Summary of Invention
Opioid receptors, G-protein coupled receptors, mediate analgesic functions, immune functions, respiratory depression, constipation, nausea, sedation, and addiction. Specifically, the ORL-1 receptor has been linked to a variety of functions, including both hyperalgesia and analgesia. This invention centers around the ORL-1 receptor (known also as the Nociceptin receptor/ earlier identified as KOR-3) and provides for research stable HEK and CHO cell lines expressing both mouse and human ORL-1. These cell lines could be used for research and/or discovery of novel therapeutic compounds. Further, these may be useful for sale and distribution to researchers interested in characterization of the ORL-1 receptor.
May be utilized as a research tool:
- For high-throughput drug screening to identify novel agonists and antagonists
- For binding experiments or generation and confirmation of antibodies against this receptor
Areas of Application
Available for licensing as a research tool.
Stage of Development
Ready for licensing. Additional stable cell lines expressing ORL-1 splice variants, as well as other opioid receptor family members with discreet binding profiles have been generated and characterized. Additional information is available upon request.
Gavril Pasternak, MD, PhD
U.S. patent issued: 6,660,496. Claims of the patent include the mouse ORL-1 coding sequence and corresponding amino acids as well as other nucleotides and amino acids with at least 95 percent homology to the mouse sequence, which includes the human ORL-1 receptor.
Jeanne Farrell, PhD